Press Release

Standard Bariatrics 7MM-Debt-Facility

Standard Bariatrics®, Inc. Secures $7 Million Debt Facility with Silicon Valley Bank

Cincinnati, Ohio–May 9, 2022Cincinnati-based Standard Bariatrics, Inc., an emerging leader in the bariatric surgery medical device field, closed a debt facility on April 27, 2022, with Silicon Valley Bank (SVB). The debt facility provides $7 million in term loans of which the first $4 million was funded at closing. The funding will be used to accelerate commercial efforts for the Titan SGS® surgical stapler and related proprietary medical devices designed for bariatric surgery.

Silicon Valley Bank is a leading investment bank partnering with innovative healthcare and technology companies. Under the terms of the new debt facility, SVB will make loans available in two tranches. The first tranche of $4 million was received at closing of which $0.4 million was used to retire existing debt. The second tranche of $3 million will be available through June 30, 2023, upon achieving certain milestones.

Cleared by the U.S. Food and Drug Administration (FDA) a year ago on April 28, 2021, the Titan SGS surgical stapler meets the new more stringent Class II product regulations for surgical staplers1. With a single firing of 55 seconds2 the Titan SGS stapler completes a 23cm staple line with no overlapping staples3. By completing the staple line in one continuous firing2, there is a reduced risk of anatomy variations associated with multiple, overlapping short-cartridge staple lines4.

Peter Donato, Chief Financial Officer at Standard Bariatrics, said, “We are pleased to continue our long-standing relationship with Silicon Valley Bank as we continue to exceed our sales and production expectations. While our balance sheet is very strong with the recent Series B equity raise, we are adding this debt facility to allow for greater speed and flexibility to accelerate our commercial efforts, further securing our supply chain and scaling our administrative capabilities.”

Karen Spilizewski, Vice President with RiverVest® and a Board Member at Standard Bariatrics said, “The clinical and technical advantages of Titan SGS are resonating with bariatric surgeons and the community of users continues to expand quickly. Early results from the 2,500 cases completed to date give us the confidence to keep investing in Titan SGS and its adjunct technologies. This debt facility will accelerate the organization’s progress toward new development milestones.”

About Standard Bariatrics, Inc.

Standard Bariatrics, Inc., is a rapidly expanding medical device company focused on the development and commercialization of products for the surgical treatment of obesity. Driven by a passionate group of surgical innovators, the Cincinnati-based organization works hand in hand with bariatric surgeons to develop and release novel solutions designed to address the growing global epidemic of obesity. The Standard Bariatrics team offers extensive experience in creating and bringing to market bariatric-related medical device technologies. They have a demonstrated record of achieving clinical excellence with economically responsible solutions for providers and their patients.

Standard Bariatrics is supported through early investment from Jobs Ohio, North Coast Angel Fund, Accelerant, Queen City Angels, CincyTech, Series A lead investors RiverVest®, Hatteras Venture Partners and Emergent Medical Partners, and Series B investors U.S. Venture Partners (USVP) and RC Capital.

About Silicon Valley Bank

For nearly 40 years, Silicon Valley Bank (SVB) has helped innovative companies and their investors move bold ideas forward, fast. SVB provides targeted financial services and expertise through its offices in innovation centers around the world. With commercial, international and private banking services, SVB helps address the unique needs of innovators. Learn more at svb.com.

  1. FDA. (2021, October 7). FDA issues final order and guidance on Surgical Staplers and staples for internal use. U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-issues-final-order-and-guidance-surgical-staplers-and-staples-internal-use
  2. U.S. Food and Drug Administration. (2021). Indications for Use. (510(k) No. K210278). Retrieved from https://www.accessdata.fda.gov/cdrh_docs/pdf21/K210278.pdf
  3. Salyer, C., Spuzzillo, A., Wakefield, D., Gomaa, D., Thompson, J., & Goodman, M. (2020 July). Assessment of a novel stapler performance for laparoscopic sleeve gastrectomy. Surgical Endoscopy, 35(7), 4016–4021. https://doi.org/10.1007/s00464-020-07858-0
  4. Toro, J., Lin, E., Patel, A., Davis, S., Sanni, A., Urrego, H., Sweeney, J., Srinivasan, J., Small, W., Mittal, P., Sekhar, A., & Moreno, C. (2014 Sept.). Association of Radiographic Morphology with Early Gastroesophageal Reflux Disease and Satiety Control after Sleeve Gastrectomy. Journal of the American College of Surgeons, 219(3), 430–438. https://doi.org/10.1016/j.jamcollsurg.2014.02.036

Media Contact
Ronald Galovich
Chief Commercial Officer, Standard Bariatrics
513.620.7751
ron@standardbariatrics.com

SBI_Achieves_Early_banner

After Successful Launch of Titan SGS® Surgical Stapler, Standard Bariatrics, Inc. Achieves Final Series B Funding Early

Cincinnati, Ohio – February 28, 2022. Cincinnati-based Standard Bariatrics, Inc., an emerging leader in the bariatric surgery medical device field, today announced completion of a $35 million Series B round ahead of schedule. The successful launch of the Titan SGS® surgical stapler completed the final milestones needed to realize the second of two tranches. The company received the remaining $9 million in funds to accelerate commercialization efforts.

“Standard Bariatrics’ performance continues to impress with their execution of key objectives including achievement of their milestones to release tranche two from the Series B raise of $35 million,” said Casey Tansey, general partner at U.S. Venture Partners and Series B investor. “The feedback from our Titan SGS users validates the company’s clinical focus for consistent, repeatable clinic outcomes for bariatric surgeons and their patients. We anticipate the company will scale rapidly in 2022, building off their early Titan SGS launch success,” he added.

The Titan SGS first-of-its-kind surgical stapler design received clearance from the U.S. Food and Drug Administration1 in April 2021, allowing it to be used in bariatric surgery requiring the creation of sleeve pouch anatomy (sleeve gastrectomy). The completion of a successful 62-patient study supported the submission.

The design ensures more consistent staple formation across the entire 23-centimeter cutline for improved staple-line strength and fewer malformed staples than competitive staplers that offer short cartridges for more general surgical use.2 Following FDA clearance, it was first used clinically in August 2021 and sales recently reached approximately $3 million.

Since then, Titan SGS has been used in over 1600 clinical cases performed in more than 35 hospital facilities across 12 states. The community of bariatric surgeons using Titan SGS is growing as they share their clinical experiences with the device.

Accomplished bariatric surgeon John Oldham, MD, Medical Director of Bariatrics for Baptist Health in Louisville, KY reached a milestone of over 250 sleeve gastrectomy procedures performed with the Titan SGS stapler. “In my 20-plus years of bariatric surgery, the Titan SGS is a game changer! Sleeves are amazing, exactly how you would want them to look!” he said.

Renowned bariatric surgeon Alex Gandsas, MD, Director of the Anne Arundel Medical Center (AAMC) Weight Loss and Metabolic Surgery Program in Annapolis recently completed the first 10 sleeve gastrectomy cases in Maryland using the Titian SGS stapler. “This is the first time in 20 years of practicing bariatric surgery that I am able to reproduce the same operation without variability, which is extremely important when it comes to accurately assessing outcomes,” he said.

Throughout the controlled launch, clinical results are positive and efficacy data continues to build. Benefits of the Titan SGS stapler include:

⦁ A stronger staple line that is more resistant to leaks 3
⦁ Staples better match patients’ native anatomy 4
⦁ Potential improvement in resolution of GERD and nausea 5
⦁ Improved procedure time and operational efficiencies 2
⦁ One (1) firing to complete the sleeve pouch anatomy 2
⦁ 88% less bleeding at the staple line 6
⦁ 82% fewer malformed staples 7

Standard Bariatrics CFO Peter Donato said, “We are pleased to announce completion of our series B funding. This will allow us to further accelerate what has already been an amazing launch with unprecedented traction even with difficult COVID-19 pandemic headwinds. I look forward to our post-COVID-19 2022 results.”

About Standard Bariatrics, Inc.

Standard Bariatrics, Inc., is a Cincinnati-based surgical procedure company focused on the innovative development and commercialization of medical devices. Driven by a passionate group of surgical innovators, the company continues to release surgical solutions designed to address significant market opportunities. A seasoned team of medical and management professionals, Standard Bariatrics has more than 175 combined years of experience in developing and commercializing novel medical device technologies with a record of achieving both clinical and economic excellence for patients and providers.

Standard Bariatrics is supported through early investment from Queen City Angels and CincyTech, Series A lead investors RiverVest®, Hatteras Venture Partners and Emergent Medical Partners, and Series B investors U.S. Venture Partners (USVP) and River Cities Capital.

For more information, visit https://www.standardbariatrics.com or call 513-620-7751.

1. U.S. Food and Drug Administration. (2021). Indications for Use. (510(k) No. K210278). Retrieved from https://www.accessdata.fda.gov/cdrh_docs/pdf21/K210278.pdf
2. Salyer, C. E., Thompson, J., Hoffman, A., Burstein, M. D., Enochs, P., Watkins, B. M., Kuethe, J., & Goodman, M. D. (2022). Multisite Study of Titan SGS Stapler in longitudinal gastric resection. Surgical Endoscopy. https://doi.org/10.1007/s00464-022-09051-x
3. Hoffman, A., Thompson, J., Hanseman, DJ. (2019). Gastric tissue stapler comparison study. Identification No. NCT04086433. Retrieved from https://clinicaltrials.gov/ct2/show/results/NCT04086433
4. Salyer, C., Spuzzillo, A., Wakefield, D., Gomaa, D., Thompson, J., & Goodman, M. (2021 July). Assessment of a novel stapler performance for laparoscopic sleeve gastrectomy. Surgical Endoscopy, 35(7), 4016–4021. https://doi.org/10.1007/s00464-020-07858-0
5. Thompson, J., Dhar, V., Hanseman, D., Watkins, B., Morton, J., & Diwan, T. (2017). Anatomy-based laparoscopic sleeve gastrectomy reduces gastroesophageal reflux disease compared to laparoscopic sleeve gastrectomy with bougie. Surgery for Obesity and Related Diseases, 13(10). https://doi.org/10.1016/j.soard.2017.09.242
6. Standard Bariatrics, Inc. 2020. Comparison of Titan SGS to Ethicon Endo-Surgery ECHELON FLEX™ GST tests on porcine model. Acute Hemostasis Report QT-0367. Internal data on file.
7. Standard Bariatrics, Inc. (2020 June) Comparison of Titan SGS to Ethicon Endo-Surgery ECHELON FLEX™ GST. Gastric Tissue Stapler Comparison Study QT-0372. Identification No. NCT04086433. Retrieved from https://clinicaltrials.gov/ct2/show/NCT04086433

Media Contact
Ronald Galovich
Chief Commercial Officer, Standard Bariatrics®
513.620.7751
ron@standardbariatrics.com

Titan SGS Passes 1,000 Clinical Case Uses

Titan SGS® from Standard Bariatrics, Inc. Passes 1,000 Clinical Case Uses

Cincinnati, Ohio – January 19, 2022

Bariatric surgeons are seeing benefits delivered to patients from the anatomy-based approach of Titan SGS® surgical stapler technology from Standard Bariatrics®, Inc. Since the first use in gastric sleeve surgery on August 24, 2021, the Titan SGS has now been used in over 1,000 clinical cases and efficacy data continues to build.

Surgeons who have used the Titan SGS in sleeve gastrectomy are reporting less operative time and less post-op patient nausea. Surgeons are also describing clean staple lines and the ease of sleeve pouch reproducibility available by using the Titan SGS. “We are very excited with the early clinical outcomes surgeons are achieving for their patients. Industry excitement continues to grow. We are fielding significant surgeon clinical interest in the technology as well as general inbound interest in Standard Bariatrics,” said Matt Sokany, CEO.

Standard Bariatrics is a Cincinnati-based company focused on developing medical devices for surgical treatments of obesity. Working alongside bariatric surgeons, they are growing a portfolio of solutions with medical devices that meet bariatric surgeons’ needs while delivering repeatable and consistent results. Technologies developed by Standard Bariatrics have been utilized in an estimated 15,000 clinical cases since the first products were commercialized.

The Titan SGS is designed to help surgeons achieve more consistent and symmetrical gastric sleeve pouch anatomy, setting patients up for the best possible outcomes. This first-of-its-kind design received FDA clearance in April 20211.

In October 2021, the FDA issued guidance on surgical staplers and staples for internal use2. The new guidelines include labeling recommendations that cover the risks specifically associated with the crossing of staple lines 2. The Titan SGS 23cm continuous staple line enables surgeons to plan and place staples in one firing3,4, minimizing variations often associated with the current use of multiple overlapping short-cartridge staple firings4.

“Optimal sleeve pouch anatomy is a function of both surgical technique and equipment utilized,” said Jonathan Thompson, MD, FACS, FASMBS, Founder and Chief Medical Officer at Standard Bariatrics.

“We are progressively building our clinical foundation for the Standard Sleeve® with Titan SGS technology. We have been focused on improving sleeve gastrectomy quality and consistency since our first clinical cases with the reusable clamp in 2016. We have worked with a terrific group of forward-thinking surgeons to establish and improve the technique of anatomy-based sleeve design. We continue to add surgeon users and evolve our equipment set to meet their needs,” added Dr. Thompson.

Bariatric surgeons across the country including California, Florida, Ohio, Kentucky, Alabama, Michigan, Texas, New Jersey, New York and North Carolina have used the Titan SGS and are gaining confidence in the reproducibility of gastric sleeve anatomy from using it.

Jon L. Schram, MD, board-certified physician specializing in bariatric surgery and weight loss management from Spectrum Health in Michigan had this to say about the Titan SGS technology: “Every sleeve looks just like the last…perfect! This is so much easier to teach and learn than expected. Because of COVID-19, we have been forced to move more of our sleeves to outpatient. Doing a better sleeve has made this very doable.”

Gustavo Bello, MD, FACS from AdventHealth Medical Group Weight Loss and Bariatric Surgery at Orlando recently used the Titan SGS during sleeve gastrectomy cases and said, “The Titan SGS sleeve anatomy now looks exactly like the pictures in the medical textbooks.” 

John Oldham, MD, Medical Director of Bariatrics for Baptist Health in Louisville, KY said, “In my 20 plus years of bariatric surgery, the Titan SGS is a game changer. Sleeves are amazing, exactly how you would want them to look.” Prior to switching to the Titan SGS stapler, Dr. Oldham utilized the Standard Clamp® technology from Standard Bariatrics.

Less than six months on the market, Titan SGS reached a $1M sales milestone during November 2021. Standard Bariatrics currently has multiple investors with a mix of Series A and Series B funding.

Surgeons interested in learning more about Titan SGS stapling technology or about applying for training and use can contact Ronald Galovich, Chief Commercial Officer of Standard Bariatrics at 513.620.7751 or ron@standardbariatrics.com.

About Standard Bariatrics®, Inc.

Standard Bariatrics, Inc., is a Cincinnati-based surgical procedure company focused on the innovative development and commercialization of medical devices. Driven by a passionate group of surgical innovators, the company continues to release surgical solutions designed to address significant market opportunities. A seasoned team of medical and management professionals, Standard Bariatrics has more than 175 combined years of experience in developing and commercializing novel medical device technologies with a record of achieving both clinical and economic excellence for patients and providers.

Standard Bariatrics is supported through early investment from Queen City Angels and CincyTech, and Series A lead investors RiverVest®, Hatteras Venture Partners and Emergent Medical Partners and more recently Series B investors U.S. Venture Partners (USVP) and River Cities Capital.

For more information, visit https://www.standardbariatrics.com or call 513.620.7751.

  1. U.S. Food and Drug Administration. (2021). Indications for Use. (510(k) No. K210278). Retrieved from https://www.accessdata.fda.gov/cdrh_docs/pdf21/K210278.pdf
  2. FDA. (2021, October 7). FDA issues final order and guidance on Surgical Staplers and staples for internal use. U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-issues-final-order-and-guidance-surgical-staplers-and-staples-internal-use
  3. Salyer, C. E., Thompson, J., Hoffman, A., Burstein, M. D., Enochs, P., Watkins, B. M., Kuethe, J., & Goodman, M. D. (2022). Multisite Study of Titan SGS Stapler in longitudinal gastric resection. Surgical Endoscopy. https://doi.org/10.1007/s00464-022-09051-x
  4. Toro, J., Lin, E., Patel, A., Davis, S., Sanni, A., Urrego, H., Sweeney, J., Srinivasan, J., Small, W., Mittal, P., Sekhar, A., & Moreno, C. (2014 Sept. 1). Association of Radiographic Morphology with Early Gastroesophageal Reflux Disease and Satiety Control after Sleeve Gastrectomy. Journal of the American College of Surgeons, 219(3), 430–438. https://doi.org/10.1016/j.jamcollsurg.2014.02.036

Media Contact
Ronald Galovich
Chief Commercial Officer, Standard Bariatrics®, Inc.
513.620.7751
ron@standardbariatrics.com

Titan SGS Reaches $1M in Sales

Standard Bariatrics, Inc. Reaches Sales Milestone with Titan SGS®

Cincinnati, Ohio –December 13, 2021

Standard Bariatrics®, Inc. (SBI), a Cincinnati-based company focused on developing medical devices for surgical treatments of obesity, announced it reached a $1M sales milestone during November 2021 for the Titan SGS®, a surgical stapler first used in gastric sleeve surgery on August 24, 2021 following FDA clearance.

By working alongside bariatric surgeons, SBI is growing a portfolio of solutions with medical devices that meet bariatric surgeons’ needs while delivering repeatable and consistent results. Bariatric surgeons across the country including California, Florida, Ohio, Kentucky, Alabama, Michigan, and North Carolina have used the Titan SGS since it was cleared by the FDA in April 20211.

The Titan SGS is designed to help surgeons achieve more consistent and symmetrical gastric sleeve pouch anatomy, setting patients up for the best possible outcomes. This first-of-its-kind design offers surgeons performing sleeve gastrectomy procedures the industry’s longest continuous staple cutline of 23 centimeters2. Surgeons can complete the sleeve pouch anatomy in a single firing2 reducing the risk of anatomy variations associated with multiple, overlapping short-cartridge staple lines3.

In October 2021, the FDA issued new guidance on surgical staplers, which now fall under a Class II designation that includes guidelines for labeling regarding risks associated with staple line crossing. Titan SGS was cleared by the FDA under these more stringent Class II guidelines1.

The first bariatric surgeon to use the Titan SGS was Aaron Hoffman, MD, FACS, Division Chief of General Surgery at the University of Buffalo (UBMD) Jacobs School of Medicine and Biomedical Sciences. Since this first use, surgeons are gaining confidence in the reproducibility of gastric sleeve anatomy from using Titan SGS.

Jon L. Schram, MD, board-certified physician specializing in bariatric surgery and weight loss management at Spectrum Health in Michigan had this to say about the Titan SGS technology: “Every sleeve looks just like the last… perfect! This is so much easier to teach and learn than expected.  Because of COVID-19, we have been forced to move more of our sleeves to outpatient. Doing a better sleeve has made this very doable.”

Gustavo Bello, MD, FACS from AdventHealth Medical Group Weight Loss and Bariatric Surgery at Orlando recently used the Titan SGS during sleeve gastrectomy cases and said, “The Titan SGS the sleeve anatomy now looks exactly like the pictures in the medical textbooks.” 

John Oldham, MD, Medical Director of Bariatrics for Baptist Health in Louisville, KY said, “In my 20 plus years of bariatric surgery, the Titan SGS is a game changer. Sleeves are amazing, exactly how you would want them to look.” Prior to switching to the Titan SGS stapler, Dr. Oldham utilized the Standard Clamp® technology from Standard Bariatrics.

Surgeons interested in learning more about Titan SGS stapling technology or about applying for training and use can contact Ronald Galovich, Chief Commercial Officer of Standard Bariatrics. at 513.620.7751 or ron@standardbariatrics.com.

About Standard Bariatrics®, Inc.

Standard Bariatrics, Inc., is a Cincinnati-based surgical procedure company focused on the innovative development and commercialization of medical devices. Driven by a passionate group of surgical innovators, the company continues to release surgical solutions designed to address significant market opportunities. A seasoned team of medical and management professionals, Standard Bariatrics has more than 175 combined years of experience in developing and commercializing novel medical device technologies with a record of achieving both clinical and economic excellence for patients and providers.

Standard Bariatrics is supported through early investment from Queen City Angels and CincyTech, and Series A lead investors RiverVest®, River Cities Capital, Hatteras Venture Partners and Emergent Medical Partners and more recently Series B investors U.S. Venture Partners (USVP).

For more information, visit https://www.standardbariatrics.com or call 513.620.7751.

  1. Indications for Use, K210278: “The Titan SGS linear cutter is intended for longitudinal transection and resection of gastric tissue for sleeve gastrectomy pouch creation.”
  2. Salyer, C. E., Thompson, J., Hoffman, A., Burstein, M. D., Enochs, P., Watkins, B. M., Kuethe, J., & Goodman, M. D. (2022). Multisite Study of Titan SGS Stapler in longitudinal gastric resection. Surgical Endoscopy. https://doi.org/10.1007/s00464-022-09051-x
  3. Toro, Lin, Patel, et al. Association of Radiographic Morphology with Early Gastroesophageal Reflux Disease and Satiety Control after Sleeve Gastrectomy. Journal of American College of Surgeons. Sep: 219(3):430-8.2014.

Media Contact
Ronald Galovich
Chief Commercial Officer, Standard Bariatrics®, Inc.
513.620.7751
ron@standardbariatrics.com

Standard Bariatrics Secures $35M in Series B Funding to Accelerate Development and Commercialization of Their First Bariatric Surgical Platform for Sleeve Gastrectomy

Cincinnati, Ohio – June 1, 2021Cincinnati-based Standard Bariatrics, Inc., has developed the Titan SGS™, a first-of-its-kind design that offers surgeons performing sleeve gastrectomy, the top bariatric surgical procedure for obesity disease, the industry’s longest continuous staple cutline of 23 centimeters.1

Standard Bariatrics®, an emerging leader in the bariatric surgery medical device field, today announced the completion of a $35M Series B round led by U.S. Venture Partners (USVP), a Silicon Valley venture capital firm that partners with entrepreneurs to transform their ideas into world-changing companies. New investor River Cities Capital joins the Series A syndication investors RiverVest® Venture Partners, Hatteras Venture Partners, Queen City Angels and Emergent Medical Partners who also participated in the Series B round.

 “U.S. Venture Partners is excited to join the team at Standard Bariatrics as they seek to transform the way bariatric surgery is delivered and improve patient outcomes,” said Casey Tansey, general partner at U.S. Venture Partners.

Standard Bariatrics is responding to the growing global obesity epidemic through the development of device solutions designed to enable surgeons to deliver more consistent and repeatable surgical outcomes. In April of 2021, the company’s Titan SGS™ stapler received clearance from the US Food and Drug Administration2 allowing the device to be used in bariatric surgery requiring the creation of sleeve pouch anatomy (sleeve gastrectomy). The submission was supported by the completion of a successful 62-patient study.

Standard Bariatrics CEO Matt Sokany said, “We are thrilled to have received clearance from the FDA in April of 2021 for our Titan SGS™ stapler. Now, completing Series B financing immediately following FDA clearance gives us the needed capital to scale our commercialization plans for the solutions we offer surgeons for use in sleeve gastrectomy and to continue developing our technology platforms.”

About Standard Bariatrics®, Inc.

Standard Bariatrics, Inc., is a Cincinnati-based surgical procedure company focused on the innovative development and commercialization of medical devices. Driven by a passionate group of surgical innovators, the company continues to release surgical solutions designed to address significant market opportunities. A seasoned team of medical and management professionals, Standard Bariatrics® has more than 175 combined years of experience in developing and commercializing novel medical device technologies with a record of achieving both clinical and economic excellence for patients and providers.

For more information, visit https://www.standardbariatrics.com or call 513-620-7751.

1. Salyer, C. E., Thompson, J., Hoffman, A., Burstein, M. D., Enochs, P., Watkins, B. M., Kuethe, J., & Goodman, M. D. (2022). Multisite Study of Titan SGS Stapler in longitudinal gastric resection. Surgical Endoscopy. https://doi.org/10.1007/s00464-022-09051-x
2. Indications for Use. K210278: “The Titan SGS linear cutter is intended for longitudinal transection and resection of gastric tissue for sleeve gastrectomy pouch creation.”

About U.S. Venture Partners

U.S. Venture Partners (USVP) is a leading Silicon Valley venture capital firm, partnering with entrepreneurs to transform their ideas into world-changing companies. USVP has invested in over 500 companies spanning four decades. USVP focuses on early-stage start-ups that transform cybersecurity, enterprise software, consumer, and healthcare. The USVP team consists of former entrepreneurs, technologists, corporate executives, and financial professionals who assist with strategy, scaling, team building, product development, and business development. USVP is based in Menlo Park, CA.

About River Cities Capital

River Cities is a growth equity firm investing in high-potential companies at the intersection of healthcare and information technology. They seek to be a business partner first and a capital provider second, investing significant human capital to leverage their domain expertise, a network of healthcare thought leaders and deep relationships with health systems assembled over a 27-year history. River Cities Capital is based in Cincinnati, OH and Raleigh, NC.

Media Contact
Ronald Galovich
Chief Commercial Officer, Standard Bariatrics®
513.620.7751
ron@standardbariatrics.com

Titan SGS

Standard Bariatrics® Titan SGS Stapling Technology for Sleeve Gastrectomy Receives FDA Clearance

Cincinnati, Ohio – May 4, 2021 – Standard Bariatrics® announced today that its novel Titan SGS™ stapling technology, designed specifically for bariatric sleeve surgery, has been cleared by the US Food and Drug Administration (FDA).1 The Titan SGS™ first-of-its-kind design offers surgeons performing sleeve gastrectomy procedures the industry’s longest continuous staple cutline of 23 centimeters.2

“This clearance marks another important milestone in our mission to create solutions that can lead to more consistent and repeatable bariatric surgery outcomes,” said Jonathan Thompson, MD, Founder and Chief Medical Officer of Standard Bariatrics®. “The Titan SGS™ stapling technology is the natural evolution of the Standard Clamp™ anatomy-based approach to sleeve gastrectomy, which has been successfully used in more than 10,000 procedures.”

With a purposeful design, driven by the needs of today’s bariatric surgeon performing sleeve gastrectomy, Titan SGS™ provides real-time audio and visual feedback, graduated staple height formation, tissue-sensing technology and a firing cycle optimized particularly for the patient’s gastric tissue during gastrectomy pouch creation.1,3,4 While every patient’s anatomy is different, the Titan SGS™ long staple line enables surgeons to plan and place staples in one firing, minimizing variations often associated with the current use of multiple overlapping short-cartridge staple firings.5  

The design ensures more consistent staple formation across the entire 23-centimeter cutline for improved staple-line strength and fewer malformed staples than competitive staplers that offer short cartridges for more general surgical use.2,3,4  The Titan SGS™ design may result in a more secure staple line and fewer chances of leaks, as evidenced with higher burst pressures.3 Because Titan SGS™ takes approximately half the time to create the staple line,6,7 it can also potentially improve procedure time and operational efficiencies.2,7

Titan SGS
Titan SGS

Titan SGS™ was cleared after a successful 62-patient multi-center trial in longitudinal gastric stapling.2 The University of Buffalo Department of Surgery in the Jacobs School of Medicine and Biomedical Sciences (UBMD) was the first to use Titan SGS™. Steven Schwaitzberg, MD, professor and chair of surgery in the Jacobs School and president of UBMD Surgery said, “Gastric sleeve is the predominant bariatric procedure in the world today and this key refinement will serve patients well for years to come.”

“We are focused on bringing innovation and breakthroughs in science and surgery to our users,” said Matt Sokany, Chief Executive Officer of Standard Bariatrics®. “We believe Titan SGS™ has the potential to overcome the challenges bariatric surgeons may encounter with the use of existing short-cartridge stapling technology.”

Surgeons interested in learning more about Titan SGS™ stapling technology or about applying for training and use can contact Ronald Galovich, Chief Commercial Officer of Standard Bariatrics®, at 513.620.7751 or ron@standardbariatrics.com.

About Standard Bariatrics®, Inc.

Standard Bariatrics, Inc., is a Cincinnati-based surgical procedure company focused on the innovative development and commercialization of medical devices. Driven by a passionate group of surgical innovators, the company continues to release surgical solutions designed to address significant market opportunities. A seasoned team of medical and management professionals, Standard Bariatrics® has more than 175 combined years of experience in developing and commercializing novel medical device technologies with a record of achieving both clinical and economic excellence for patients and providers.

Standard Bariatrics® is supported through early investment from Queen City Angels and CincyTech, and more recently Series A lead investors RiverVest®, Hatteras Venture Partners and Emergent Medical Partners.

For more information, visit https://www.standardbariatrics.com or call 513-620-7751.

1. Indications for Use, K210278: “The Titan SGS linear cutter is intended for longitudinal transection and resection of gastric tissue for sleeve gastrectomy pouch creation.”
2. Salyer, C. E., Thompson, J., Hoffman, A., Burstein, M. D., Enochs, P., Watkins, B. M., Kuethe, J., & Goodman, M. D. (2022). Multisite Study of Titan SGS Stapler in longitudinal gastric resection. Surgical Endoscopy. https://doi.org/10.1007/s00464-022-09051-x
3. Slayer, Spuzzillo, Wakefield, et al.  Assessment of a novel stapler performance for laparoscopic sleeve gastrectomy.2020
4. Yeo, Thompson, Hanseman, Diwan, Dunki-Jacobs, et al. Increased staple loading pressures and reduced staple heights in laparoscopic sleeve gastrectomy reduce intraoperative bleeding.2020
5. Toro, Lin, Patel, et al. Association of Radiographic Morphology with Early Gastroesophageal Reflux Disease and Satiety Control after Sleeve Gastrectomy.2014
6. Titan Pre-clinical 510K data on file
7. Varban, Niemann, Stricklen, et al. Far from Standardized. Journal of Laparoendoscopic & Advanced Surgical techniques.2107

Media Contact
Ronald Galovich
Chief Commercial Officer, Standard Bariatrics®
513.620.7751
ron@standardbariatrics.com

Board_Kurt-Azarbarzin

Standard Bariatrics Names Kurt Azarbarzin as Chairman of the Board of Directors

Azarbarzin brings vast experience in medical devices, surgical stapling, innovation, and successful execution of growth strategies

Blue Ash, OH – January 30, 2019 – Standard Bariatrics, Inc. today announced the appointment of Kurt Azarbarzin as Chairman of the Board of Directors, effective immediately.

Azarbarzin, currently serving as Chief Technology Officer at CONMED Corporation (“CONMED”), brings 35 years of experience in the medical device industry. Prior to joining CONMED, he was Founder and CEO of SurgiQuest, Inc. (“SurgiQuest”), a privately-held venture-backed company that developed, manufactured, and marketed innovative access technologies for minimally invasive surgery. While at SurgiQuest, he commercialized, financed, and led a growth strategy that created significant shareholder value and resulted in a successful acquisition of the company by CONMED for $265 million in November 2015. Prior to SurgiQuest, Azarbarzin spent 21 years at United States Surgical Corporation/Tyco, most recently as Global Vice President of Research and Development.

“Kurt’s broad industry experience and background will significantly strengthen our Board of Directors,” said Dr. Jon Thompson, Founder of Standard Bariatrics. “We look forward to Kurt’s valuable contributions as we remain focused on consistent outcomes for patients undergoing Sleeve Gastrectomy, using our surgical instrumentation.”

Azarbarzin commented, “I am very pleased to join the talented Standard Bariatrics team, and excited about complementing the company’s ongoing strategic efforts. I look forward to working with the experienced Board and management team as they continue to drive innovation and pursue compelling market opportunities.”

Azarbarzin sits on the Board of TELA® Bio, Inc., a surgical reconstruction company and is a member of the Executive Board at the Center for BioMedical Innovation and Technology at Yale University.

About Standard Bariatrics, Inc.
Standard Bariatrics, Inc. is a Cincinnati-based surgical procedure company focused on the innovative development and commercialization of medical devices. Driven by a passionate group of surgical innovators, the company will continue to release surgical solutions designed to address significant market opportunities. The Standard Bariatrics management team has over 175 combined years of experience in developing and commercializing novel medical device technologies with a record of achieving both clinical and economic excellence for patients and providers. Standard Bariatrics is supported through early investment from Queen City Angels CincyTech and Accelerant, more recently, series A lead investors RiverVest and Hatteras. For more information, visit https://www.standardbariatrics.com or call 513-620-7751.